Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections

ABSTRACT: Objectives: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Helen L. Zhang, Leigh Cressman, Ebbing Lautenbach
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Meropenem/vaborbactam Carbapenem-resistant Enterobacterales CRE Multidrug-resistant organisms Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/94ac77b172b04ac2b1060dd9d664631d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94ac77b172b04ac2b1060dd9d664631d
record_format	dspace
spelling	oai:doaj.org-article:94ac77b172b04ac2b1060dd9d664631d2021-11-28T04:32:20ZReal-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections2213-716510.1016/j.jgar.2021.09.015https://doaj.org/article/94ac77b172b04ac2b1060dd9d664631d2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2213716521002393https://doaj.org/toc/2213-7165ABSTRACT: Objectives: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections. Methods: This study included adult patients with MVB-susceptible CRE infection who received ≥48 h of MVB. Clinical and microbiological outcomes were ascertained via chart review. Results: Among 15 patients with CRE infection who were treated with MVB, 9 (60.0%) had a positive clinical response. Among five patients with CRE bone and joint infection, three (60.0%) experienced a positive clinical response. One patient developed a microbiologically confirmed recurrent CRE infection and one patient developed Clostridioides difficile infection. Conclusion: MVB was well tolerated and effective for the majority of patients in this case series.Helen L. ZhangLeigh CressmanEbbing LautenbachElsevierarticleMeropenem/vaborbactamCarbapenem-resistant EnterobacteralesCREMultidrug-resistant organismsMicrobiologyQR1-502ENJournal of Global Antimicrobial Resistance, Vol 27, Iss , Pp 299-302 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Meropenem/vaborbactam Carbapenem-resistant Enterobacterales CRE Multidrug-resistant organisms Microbiology QR1-502
spellingShingle	Meropenem/vaborbactam Carbapenem-resistant Enterobacterales CRE Multidrug-resistant organisms Microbiology QR1-502 Helen L. Zhang Leigh Cressman Ebbing Lautenbach Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
description	ABSTRACT: Objectives: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections. Methods: This study included adult patients with MVB-susceptible CRE infection who received ≥48 h of MVB. Clinical and microbiological outcomes were ascertained via chart review. Results: Among 15 patients with CRE infection who were treated with MVB, 9 (60.0%) had a positive clinical response. Among five patients with CRE bone and joint infection, three (60.0%) experienced a positive clinical response. One patient developed a microbiologically confirmed recurrent CRE infection and one patient developed Clostridioides difficile infection. Conclusion: MVB was well tolerated and effective for the majority of patients in this case series.
format	article
author	Helen L. Zhang Leigh Cressman Ebbing Lautenbach
author_facet	Helen L. Zhang Leigh Cressman Ebbing Lautenbach
author_sort	Helen L. Zhang
title	Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
title_short	Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
title_full	Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
title_fullStr	Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
title_full_unstemmed	Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
title_sort	real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant enterobacterales infections
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/94ac77b172b04ac2b1060dd9d664631d
work_keys_str_mv	AT helenlzhang realworldclinicaloutcomesofmeropenemvaborbactamfortreatmentofcarbapenemresistantenterobacteralesinfections AT leighcressman realworldclinicaloutcomesofmeropenemvaborbactamfortreatmentofcarbapenemresistantenterobacteralesinfections AT ebbinglautenbach realworldclinicaloutcomesofmeropenemvaborbactamfortreatmentofcarbapenemresistantenterobacteralesinfections
_version_	1718408331100422144

Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections

Ejemplares similares